Cytokinetics Names Robert E. Landry to Board of Directors
Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential CommercializationSOUTH SAN FRANCISCO, Calif., ...
REGN Shareholders Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Class Action Lawsuit - Contact Bronstein, Gewirtz and Grossman, LLC Today!
NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors
This was the stock's second consecutive day of losses.
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Regeneron Pharmaceuticals REGN Get Free Report has outperformed the market over the past 15 years by 12.37% on an annualized ...
Yahoo Finance4d
Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock
The fact that multiple Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors.
Morningstar4d
The Gross Law Firm Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN
NEW YORK, Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN ...
Finanznachrichten3d
Regeneron Pharmaceuticals, Inc.: Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA ...
Morningstar4d
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit
NEW YORK, Feb. 10, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2 ...
Yahoo Finance3d
Regeneron Announces Investor Conference Presentations
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
Shares of Regeneron Pharmaceuticals Inc. slid 3.61% to $665.46 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.03% to 6,068.
Nasdaq3d
Regeneron Pharmaceuticals' Linvoseltamab BLA Resubmission Accepted by FDA for Review in Relapsed/Refractory Multiple Myeloma
TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the ...